Hamza, S. Et Al. 2024. Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer. PHARMACEUTICALS , vol.17, no.3 , 1-20.

Hamza, S., Garanina, E. E., Shkair, L., Alsaadi, M., Khaiboullina, S. F., & Tezcan, G., (2024). Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer. PHARMACEUTICALS , vol.17, no.3, 1-20.

Hamza, Shaimaa Et Al. "Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer," PHARMACEUTICALS , vol.17, no.3, 1-20, 2024

Hamza, Shaimaa Et Al. "Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer." PHARMACEUTICALS , vol.17, no.3, pp.1-20, 2024

Hamza, S. Et Al. (2024) . "Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer." PHARMACEUTICALS , vol.17, no.3, pp.1-20.

@article{article, author={Shaimaa Hamza Et Al. }, title={Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer}, journal={PHARMACEUTICALS}, year=2024, pages={1-20} }